Ramalho Antonio Sérgio, Magna Luís Alberto, de Paiva-e-Silva Roberto Benedito
Departamento de Genética Médica, Faculdade de Ciências Médicas, Universidade Estadual de Campinas, Campinas, SP, 13081-970, Brasil.
Cad Saude Publica. 2003 Jul-Aug;19(4):1195-9. doi: 10.1590/s0102-311x2003000400040. Epub 2003 Sep 8.
By including hemoglobinopathies in the National Neonatal Screening Program (PNTN), Brazilian Ministry of Health Directive # 822/01 has taken an important step towards recognition of their relevance for public health in the country. However, except at a few specialized centers, the public health care system is unprepared to meet the goals laid out under the directive. As the first step to effectively implement the guidelines, it is thus necessary to disseminate information on hemoglobinopathies among health professionals working in public health, especially those involved in neonatal screening. This article discusses some of the unique characteristics of hemoglobinopathies in comparison to other metabolic disorders included in the National Neonatal Screening Program. The authors also analyze potential sources of misunderstanding that could jeopardize the program's outcome.
通过将血红蛋白病纳入国家新生儿筛查计划（PNTN），巴西卫生部第822/01号指令朝着承认其在该国公共卫生领域的相关性迈出了重要一步。然而，除了少数几个专业中心外，公共卫生保健系统尚无准备好实现该指令规定的目标。因此，作为有效实施这些指导方针的第一步，有必要在从事公共卫生工作的专业人员中，特别是那些参与新生儿筛查的人员中传播有关血红蛋白病的信息。本文讨论了与国家新生儿筛查计划中包括的其他代谢紊乱相比，血红蛋白病的一些独特特征。作者还分析了可能危及该计划结果的潜在误解来源。
